Market Research Industry Reports

Stroke - Pipeline Review, H2 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS

Stroke - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Stroke - Pipeline Review, H2 2018, provides an overview of the Stroke (Cardiovascular) pipeline landscape.

Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear suddenly. Initially, the person may feel sick, and look pale and very unwell. They may complain of a sudden headache. They may have sudden numbness in their face or limbs, particularly down one side of their body. They may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Stroke - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and latest news and press releases.

The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 26, 23, 2, 104, 15 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 31 and 4 molecules, respectively.

Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhance decision-making capabilities and help to create effective counter-strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real-time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on a mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Stroke (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with the potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from a pipeline.

Table of Contents
Table of Contents 2
Introduction 7
Stroke - Overview 8
Stroke - Therapeutics Development 9
Stroke - Therapeutics Assessment 34
Stroke - Companies Involved in Therapeutics Development 50
Stroke - Drug Profiles 91
Stroke - Dormant Projects 495
Stroke - Discontinued Products 508
Stroke - Product Development Milestones 511
Appendix 522


List Of Tables


Number of Products under Development for Stroke, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Stroke - Pipeline by Acorda Therapeutics Inc, H2 2018
Stroke - Pipeline by Acticor Biotech SAS, H2 2018
Stroke - Pipeline by Addex Therapeutics Ltd, H2 2018
Stroke - Pipeline by Affibody AB, H2 2018
Stroke - Pipeline by Amarantus Bioscience Holdings Inc, H2 2018
Stroke - Pipeline by Anavex Life Sciences Corp, H2 2018
Stroke - Pipeline by Antoxis Ltd, H2 2018
Stroke - Pipeline by Apellis Pharmaceuticals Inc, H2 2018
Stroke - Pipeline by AptaTargets SL, H2 2018
Stroke - Pipeline by ArmaGen Inc, H2 2018
Stroke - Pipeline by Artelo Biosciences Inc, H2 2018
Stroke - Pipeline by ArunA Biomedical Inc, H2 2018
Stroke - Pipeline by AstraZeneca Plc, H2 2018
Stroke - Pipeline by Athersys Inc, H2 2018
Stroke - Pipeline by BioAxone BioSciences Inc, H2 2018
Stroke - Pipeline by Biogen Inc, H2 2018
Stroke - Pipeline by BioTime Inc, H2 2018
Stroke - Pipeline by Boehringer Ingelheim GmbH, H2 2018
Stroke - Pipeline by Cardax Inc, H2 2018
Stroke - Pipeline by Celltrion Inc, H2 2018
Stroke - Pipeline by CHA Bio & Diostech Co Ltd, H2 2018
Stroke - Pipeline by CohBar Inc, H2 2018
Stroke - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Stroke - Pipeline by DiaMedica Therapeutics Inc, H2 2018
Stroke - Pipeline by Diffusion Pharmaceuticals Inc, H2 2018
Stroke - Pipeline by Epigen Biosciences Inc, H2 2018
Stroke - Pipeline by Evgen Pharma Plc, H2 2018
Stroke - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Stroke - Pipeline by Fina Biotech SL, H2 2018
Stroke - Pipeline by Freeox Biotech SL, H2 2018
Stroke - Pipeline by GC Pharma, H2 2018
Stroke - Pipeline by Genervon Biopharmaceuticals LLC, H2 2018
Stroke - Pipeline by Glialogix Inc, H2 2018
Stroke - Pipeline by Glucox Biotech AB, H2 2018
Stroke - Pipeline by Immunwork Inc, H2 2018
Stroke - Pipeline by Instituto Biomar SA, H2 2018
Stroke - Pipeline by International Stem Cell Corp, H2 2018
Stroke - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2018
Stroke - Pipeline by JT Pharmaceuticals Inc, H2 2018
Stroke - Pipeline by Les Laboratoires Servier SAS, H2 2018
Stroke - Pipeline by Living Cell Technologies Ltd, H2 2018
Stroke - Pipeline by Lixte Biotechnology Holdings Inc, H2 2018
Stroke - Pipeline by Lumosa Therapeutics Co Ltd, H2 2018
Stroke - Pipeline by M et P Pharma AG, H2 2018
Stroke - Pipeline by Mapreg SAS, H2 2018
Stroke - Pipeline by Meridigen Biotech Co Ltd, H2 2018
Stroke - Pipeline by Neuralstem Inc, H2 2018
Stroke - Pipeline by Neuren Pharmaceuticals Ltd, H2 2018
Stroke - Pipeline by Neurofx Inc, H2 2018
Stroke - Pipeline by NeuroNascent Inc, H2 2018
Stroke - Pipeline by NeurOp Inc, H2 2018
Stroke - Pipeline by New World Laboratories Inc, H2 2018
Stroke - Pipeline by Nipro Corp, H2 2018
Stroke - Pipeline by NoNO Inc, H2 2018


List Of Figures


Number of Products under Development for Stroke, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018


Stroke - Pipeline Review, H2 2018

Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a

USD 2000View Report

Acute Ischemic Stroke: Epidemiology Forecast to 2027

Acute Ischemic Stroke: Epidemiology Forecast to 2027A stroke occurs when blood to the brain is either blocked or interrupted by blood clots or ruptured blood vessels; this deprives the brain

USD 3995View Report

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2018

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2018According to the recently published report Transmembrane Prolyl 4 Hydroxylase -

USD 3500View Report

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2018

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2018CD40 Ligand (T

USD 3500View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Sep 2018
No. of Pages :544
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube